You are viewing AANS Neurosurgeon Volume 26, Number 2, 2017. View our current issue, Volume 26, Number 4, 2017

AANS Neurosurgeon | Volume 26, Number 2, 2017

Advertisement

Alzheimer's Drug Targeting Soluble Amyloid Falls Short in a Large Clinical Trial

A paper reports that solanezumab, a monoclonal antibody-based treatment for Alzheimer’s disease developed by Eli Lilly that targets amyloid plaques, did not significantly slow cognitive decline.

Columbia University Irving Medical Center (CUIMC) led the multicenter study.

Researchers have proposed that Alzheimer’s disease is caused by the buildup of a sticky protein called beta-amyloid. According to this ‘amyloid hypothesis,’ the protein forms plaques in the brain that damage and eventually destroy brain cells. Solanezumab was designed to reduce the level of soluble amyloid molecules before they aggregate. 

Click here to read more.

Calendar/Courses

Winter Clinics for Cranial and Spinal Surgery
Feb. 25, 2018 - Mar. 1, 2018; Snowmass Village, Colo.

69th Southern Neurosurgical Society Annual Meeting
Feb. 28, 2018 - Mar. 3, 2018; San Juan, PR

Second International Brain Mapping Course
April 26-27, 2018; New Orleans

Leave a Reply

Be the first to reply using the above form.